Dexcom ((DXCM)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Study Overview: The COMPASS Program, officially titled ‘Continuous Monitoring, Peer And Structured Support for Management of Uncontrolled Type 2 Diabetes,’ is a prospective single-arm study aimed at evaluating the efficacy of a virtual group visit program using continuous glucose monitoring (CGM) to improve glucose levels and quality of life in individuals with uncontrolled type 2 diabetes. This study is significant as it explores the integration of technology and peer support in diabetes management.
Intervention/Treatment: The study tests a behavioral intervention comprising education, lifestyle counseling, and peer support. Participants will engage in virtual group visits focusing on CGM usage, nutrition, movement, stress reduction, and habit formation to manage blood sugar levels effectively.
Study Design: This observational study follows a cohort model with a prospective time perspective. Participants are observed over time to assess the impact of the virtual group visit program on diabetes management without any masking or allocation.
Study Timeline: The study began on June 27, 2025, with recruitment currently ongoing. The primary completion and estimated completion dates are yet to be announced. The last update was submitted on the same day the study started, indicating the study’s active status.
Market Implications: This study update could positively influence Dexcom’s stock performance by showcasing the potential of CGM technology in improving diabetes management. As Dexcom collaborates with Whole Endo, successful outcomes may enhance investor confidence and position the company favorably against competitors in the diabetes care market.
The study is ongoing, with further details available on the ClinicalTrials portal.